Collaboration

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Retrieved on: 
Monday, April 1, 2024
Research, Biotechnology, Other Health, Health, Cosmetics, Pharmaceutical, Retail, Science, Oncology, Dermatology, Vitiligo, Prurigo nodularis, Patient, Collaboration, Asthma, JAK1, HS, Hidradenitis suppurativa, PN, CMS, Autoimmunity, Pharmaceutical industry

Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.

Key Points: 
  • Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.
  • Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
  • CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.
  • “We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Hervé Hoppenot, Chief Executive Officer, Incyte.

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

Retrieved on: 
Wednesday, March 27, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, HCC, AbbVie, GPCR, Ulcerative colitis, Head, Alpha globulin, Survival, Data science, Data analysis, Drug discovery, Partnership, Hook effect, HNSCC, Boehringer Ingelheim, Inflammation, Patient, Research, RNA, Veloxis Pharmaceuticals, Cancer, Lung cancer, Bank statement, AACR, Investment, First, Therapy, ESMO, Collaboration, Hepatocellular carcinoma, RNA therapeutics, FDA, Artificial intelligence, Audit committee, Food, Pharmaceutical industry

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.
  • Anne-Laure Autret-Cornet, Chief Financial Officer of OSE Immunotherapeutics, adds: “Our business-model is mostly based on recurrent and strategic partnerships with pharmaceutical companies.
  • A meeting of the Board of Directors of OSE Immunotherapeutics was held on March 27, 2024.
  • Following the Audit Committee opinion, the Board approved the annual and consolidated financial statements prepared under IFRS on 31 December 2023.

Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer

Retrieved on: 
Tuesday, March 26, 2024
Software, Research, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, Microsoft, Chromosome, Microsoft Research, Survival, Patient, Biomarker, Nature, Cancer, AI, CIN, Human, Medicine, MBA, FRCP, Therapy, CRISPR, Collaboration, Medical imaging

Volastra leads the field in development of therapeutics that target chromosomal instability (CIN), a key characteristic of cancer associated with accelerated disease progression, increased resistance to therapies, and shortened patient survival.

Key Points: 
  • Volastra leads the field in development of therapeutics that target chromosomal instability (CIN), a key characteristic of cancer associated with accelerated disease progression, increased resistance to therapies, and shortened patient survival.
  • While CIN is a hallmark of cancer, levels of CIN vary widely across tumor types from being nearly ubiquitous in some to only partially present in others.
  • Volastra’s two KIF18A inhibitors are in parallel Phase 1 clinical trials treating tumor types with near-universally high levels of CIN.
  • We are excited to apply our proprietary precision medicine platform to clinical trials in the rapidly advancing field of KIF18A inhibition.”

Adobe Summit 2024: Adobe Unveils the Future of Customer Experience Management (CXM) in the Age of Generative AI

Retrieved on: 
Tuesday, March 26, 2024
Technology, Mobile, Wireless, Audio, Video, Apps, Applications, Artificial Intelligence, Other Technology, Software, Digital Marketing, Networks, Communications, Internet, Data Management, Content Marketing, Consumer Electronics, Cloud, CDP, Customer experience, Pfizer, Climate, Social media, Microsoft Azure, Havas, Investment, Asset management, Asset, Media, Marketing, TSB, IPG, General Motors, Publicis, Microsoft Word, Microsoft, Partnership, Workflow, Adobe Experience Cloud, Firefly, AEM, Delta Air Lines, Customer data platform, Data management, Creation, Organization, CXM, Collaboration, Research, OneTrust, Activation, AI, IBM, Imagination, Adobe Creative Cloud, Accenture, B2B, ADBE, Conference, Growth, AJO, Omnicom Group, BigQuery, EY, Life, Google Docs, MLB, Summit, WPP, Multimedia, Sales

In the era of generative AI, Adobe is providing a roadmap to help brands activate AI to deliver customer value and capture the massive opportunity in driving personalization at scale.

Key Points: 
  • In the era of generative AI, Adobe is providing a roadmap to help brands activate AI to deliver customer value and capture the massive opportunity in driving personalization at scale.
  • This is anchored in Adobe Experience Platform, which enables brands to activate customer data across various enterprise systems through an integrated set of applications.
  • Adobe announced today an expanded partnership with Microsoft to deliver generative AI capabilities for marketers that bring powerful Adobe Experience Cloud customer experience insights and Firefly generative AI directly into Microsoft applications to reinvent workflows and ignite productivity.
  • Adobe Summit 2024 is a hybrid event with both an in-person and online presentation powered by Adobe Experience Cloud.

 ISG to Publish Reports on Workplace Services, Solutions

Retrieved on: 
Tuesday, March 26, 2024
Technology, Mobile, Wireless, Human Resources, Consulting, Public Policy, Government, Professional Services, Other Technology, Software, Networks, Internet, Hardware, State, Local, Data Management, Security, DEX, Freedom, SMB, Collaboration, Research, URL, ISG, CX, Public sector, Lob, Workflow, Future, Management

The reports, scheduled to be released in September, will evaluate providers of services including workplace strategy and enablement, next-gen employee experience transformation, managed end-user technology, continuous productivity support, and smart and sustainable workplace services, as well as solutions for the large enterprise, SMB and the public sector markets.

Key Points: 
  • The reports, scheduled to be released in September, will evaluate providers of services including workplace strategy and enablement, next-gen employee experience transformation, managed end-user technology, continuous productivity support, and smart and sustainable workplace services, as well as solutions for the large enterprise, SMB and the public sector markets.
  • “Employees seek the freedom to select both their workspace and the required technology,” said Iain Fisher, director, ISG Provider Lens Research.
  • In addition, ISG has distributed surveys to more than 60 providers of Future of Work solutions globally.
  • Connected and Collaborative Work Solutions, evaluating providers offering software solutions to support working with a team of remote and in-office employees sharing a virtual workplace, including content collaboration, project/task management, note-taking and content creation.

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 25, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Stoke, Acadia Pharmaceuticals, Therapy, Collaboration, License, Cryptocurrency

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2023.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2023.
  • As of December 31, 2023, Stoke had $201.4 million in cash, cash equivalents, and marketable securities, which is anticipated to fund operations to the end of 2025.
  • Research and development expenses for the year ended December 31, 2023 were $82.2 million, compared to $77.8 million for 2022.
  • General and administrative expenses for the year ended December 31, 2023 were $41.3 million, compared to $38.9 million for 2022.

Insurity Partners with OIP Robotics to Transform Data Processing Through AI

Retrieved on: 
Tuesday, March 19, 2024
Technology, Insurance, Fintech, Professional Services, Software, Networks, Robotics, Data Management, Artificial Intelligence, Automation, Organization, Documentation, Software as a service, Risk management, Partnership, Risk, Policy, AI, System, P&C, Collaboration

Insurity , the leading provider of cloud software for insurance carriers, brokers, and MGAs, today announced that it has partnered with OIP Robotics (OIPR), an Insurtech data and software solutions lab, to transform data processing within P&C insurance.

Key Points: 
  • Insurity , the leading provider of cloud software for insurance carriers, brokers, and MGAs, today announced that it has partnered with OIP Robotics (OIPR), an Insurtech data and software solutions lab, to transform data processing within P&C insurance.
  • This collaboration is set to bring unparalleled automation efficiency to policy lifecycle management and transform traditional data processing methods, bringing increased operational efficiencies and reduced costs to insurance organizations.
  • By integrating OIPR’s innovative AI capabilities with Insurity’s advanced SaaS offerings, Insurity customers get the benefit of streamlined processing using a single document entry point feeding Insurity’s entire product suite.
  • This efficiency enhances operational processes and significantly lowers the risk of claims related to data entry errors, thereby safeguarding customer interests.

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ODD, Cancer, Research, PRMT5, Brain, Mutation, BRCA, NSCLC, NYU Langone Health, Breast, General counsel, Patient, GBM, Orphan, Collaboration, DNA, DevOps, MTAP, Sarcoma, Head, MTA, AACR, Glioblastoma, Clinical trial, PARP, Therapy, Drug development, ATM, ACS, Safety, Pharmacokinetics, Carcinoma, Corporate governance, FDA, American Chemical Society, Food, Pharmaceutical industry

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.

Key Points: 
  • Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.
  • “In 2023, we made meaningful progress developing precision oncology treatments and now have four ongoing phase 1/2 clinical trials.
  • The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to TNG462 in December 2023 for the treatment of soft tissue sarcomas.
  • The increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.

F+L Week 2025 - A Milestone Celebration of Innovation and Leadership

Retrieved on: 
Monday, March 18, 2024
Automotive, Automotive Manufacturing, Oil, Gas, Manufacturing, Energy, Alternative Vehicles, Fuels, Other Manufacturing, Poster, Collaboration, City, Lubricant, Original equipment manufacturer, JASO

Since its inception in 1995, F+L Week has been at the forefront of industry innovation, serving as a pivotal platform for knowledge exchange, networking, and groundbreaking announcements.

Key Points: 
  • Since its inception in 1995, F+L Week has been at the forefront of industry innovation, serving as a pivotal platform for knowledge exchange, networking, and groundbreaking announcements.
  • As we celebrate this landmark 30th anniversary, we look back on a history rich with collaboration, innovation, and progress.
  • Through initiatives like the F&L Asia Awards, F+L Week continues to champion excellence and inspire advancements within the fuels and lubricants domain.
  • Set against the stunning backdrop of Bali, Indonesia, F+L Week 2025 is more than an event—it's a milestone in the fuels and lubricants industry.

Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights

Retrieved on: 
Monday, March 11, 2024
Research, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Johnson & Johnson, Growth, Drug discovery, Exercise, Partnership, Webcast, Patient, Committee, Collaboration, Nature, Senior, Lenalidomide, Investment, Investigational New Drug, Delta, ODAC, Janssen, CHMP, Food

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its fourth quarter and full year 2023 unaudited financial results and key corporate highlights.

Key Points: 
  • Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its fourth quarter and full year 2023 unaudited financial results and key corporate highlights.
  • Financial Results for Quarter and Year Ended December 31, 2023
    As of December 31, 2023, Legend Biotech had approximately $1.3 billion of cash and cash equivalents, time deposits, and short-term investments.
  • There was no license revenue for the three months ended December 31, 2023, and December 31, 2022.
  • License revenue for the year ended December 31, 2023, was $35.2 million, compared to $50.0 million for the year ended December 31, 2022.